[26G-pm] Cancer-3

Sat. Mar 26, 2022 4:54 PM - 5:54 PM [Room G] Exhibition Room 212 (Bldg. 2: 1F)

Chair: Kazunori Akimoto

+Add all to schedule

4:54 PM - 5:06 PM

[26G-pm18S] The acetogenin analog JCI-20679 suppresses glioblastoma stem cells proliferation via increasing p-AMPK protein levels and decreasing NFATc2 expression levels

○Shota Ando¹, Naoto Kojima¹, Chiami Moyama¹, Mitsugu Fujita², Hiromi Ii¹, Susumu Nakata¹ (1. Kyoto Pharm Univ, 2. Faculty of Med Kindai Univ)

5:06 PM - 5:18 PM

[26G-pm19S] Elucidation of antitumor mechanism targeting Stat5b in mouse glioblastoma model

○Chiami Moyama¹, Mitsugu Fujita², Shota Ando¹, Hiromi Ii³, Susumu Nakata³ (1. Grad. Sch. Pharm. Sci., Kyoto Pharm Univ., 2. Faculty of Med., Kindai Univ., 3. Kyoto Pharm Univ.)

5:18 PM - 5:30 PM

[26G-pm20] Role of Selenoprotein P on the growth of glioblastoma and its significance as therapeutic target

Hikari Sugiura¹, Xi Zhen¹, Misaki Shimizu¹, ○Takashi Toyama¹, Yoshiro Saito¹ (1. Graduate School of Pharmaceutical Sciences, Tohoku University)

5:30 PM - 5:42 PM

[26G-pm21] Development of a novel anti-cancer immunotherapy based on tumor immunogenicity improvement by the interaction between abacavir and HLA-B*57:01

○Takeshi Susukida¹, Shigeki Aoki², Tomohiro Shirayanagi², Kousei Ito², Yoshihiro Hayakawa¹ (1. Laboratory of Cancer Biology and Immunology, Section of Host Defences, Institute of Natural Medicine, University of Toyama, 2. Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University)

5:42 PM - 5:54 PM

[26G-pm22] An RSK inhibitor BI-D1870 suppressed the growth of acute myeloid leukemia

○Kazuhiro Katayama¹ (1. Sch. Pharm., Nihon Univ.)

Session information